Pyrimido [4,5-B] -Oxazines For Use as Dgat Inhibitors
申请人:Birch Alan Martin
公开号:US20080306059A1
公开(公告)日:2008-12-11
Compounds of formula (I) or salts thereof, wherein A, and R
1
to R
5
are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.
PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS
申请人:Birch Alan Martin
公开号:US20100311737A1
公开(公告)日:2010-12-09
Compounds of formula (I) or salts thereof, wherein A, and R
1
to R
5
are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.
PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS
申请人:AstraZeneca AB
公开号:EP1966221A1
公开(公告)日:2008-09-10
SSAO INHIBITORS AND USES THEREOF
申请人:METACRINE, INC.
公开号:US20200181104A1
公开(公告)日:2020-06-11
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.